Company General Biotech Srl with Fiscal Code 30356876
recorded a turnover of 2024 of
1.189.475,
with a net profit of
-643.752
and having an average number of employees of
25.
The company operates in the field of Lucrări de construcţii a proiectelor utilitare pentru fluide having the NACE code 4221.
Sales - Ron
Sales, Profit, Employees, Total Income, Financial Results -
General Biotech Srl
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Sales - EUR
434.393
742.453
1.555.061
964.459
774.535
1.867.250
1.371.739
1.324.477
2.209.704
1.189.475
Total Income - EUR
434.448
1.015.024
1.323.987
978.138
1.124.467
1.640.606
1.599.205
1.523.378
1.965.218
1.331.109
Total Expenses - EUR
338.525
980.339
1.096.192
762.778
1.012.942
1.579.652
1.538.073
1.473.904
1.890.561
1.974.861
Gross Profit/Loss - EUR
95.923
34.685
227.795
215.360
111.525
60.954
61.131
49.474
74.658
-643.752
Net Profit/Loss - EUR
80.957
27.856
185.072
177.595
103.748
47.318
48.001
39.974
62.554
-643.752
Employees
1
2
5
11
11
14
17
21
27
25
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded.
In the last year of activity, the sales decreased by -45.9%, from 2.209.704 euro in the year 2023, to 1.189.475 euro in 2024.
The Net Profit decreased by -62.204 euro, from 62.554 euro in 2023, to 0 in the last year.
Check the financial reports for the company - General Biotech Srl
Financial Rating - GENERAL BIOTECH SRL
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Financial Rating
Payment Limits - General Biotech Srl
See the company's payment capacity for situations in which you conclude contracts with payment terms.
Check Payment Limits
Prob. of insolvency - General Biotech Srl
It determines the risk of insolvency based on the submitted accounting balance.
Insolvency Probability
Financial Reports - General Biotech Srl
Check all the financial reports of the company and know the risks in collaboration with it.
Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
Debts, Equity, Inventories, Receivables, Accounts, Assets -
General Biotech Srl - CUI 30356876
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Fixed Assets
1.710
29.426
119.372
96.226
71.355
44.831
25.045
11.513
14.684
13.995
Current Assets
235.977
1.057.719
1.049.918
463.891
671.371
822.744
1.260.584
1.012.296
1.243.887
1.174.522
Inventories
0
242.918
33.492
24.623
372.013
161.316
402.830
592.710
343.348
440.987
Receivables
190.298
792.675
1.009.356
426.372
292.573
648.135
809.256
312.804
846.941
732.225
Cash
45.679
22.125
7.070
8.602
6.784
13.293
48.498
106.781
53.598
1.310
Shareholders Funds
79.349
32.256
187.520
177.641
147.718
61.125
51.324
49.628
82.877
-610.644
Social Capital
45
45
44
43
42
41
40
41
40
40
Debts
158.828
1.057.141
985.015
384.567
600.151
816.685
1.247.166
981.773
1.181.345
1.807.509
Income in Advance
0
315.822
0
0
0
0
0
0
0
0
Exchange rate - RON
4.9743
4.9465
4.9315
4.9468
4.8371
4.7454
4.6535
4.5681
4.4908
4.445
Main CAEN
"4221 - 4221"
CAEN Financial Year
4221
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
1.174.522 euro in 2024 which includes Inventories of
440.987 euro, Receivables of
732.225 euro and cash availability of
1.310 euro.
The company's Equity was valued at
-610.644 euro, while total Liabilities amounted to
1.807.509 euro.
Equity decreased by -693.058 euro, from 82.877 euro in 2023, to -610.644 in 2024.
Similar services useful for checking companies and business development.
SellNet
Get the contact details for any company and get in touch with it.
Sectoral Studies
Knows the market and develops its own development strategies according to sectorial data.
Databases
Export in excel files the data of the companies selected according to the desired criteria.
Import - Export
Find importers and exporters according to the type of activity and the countries in which they carry it out.
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - General Biotech Srl